Why Is OmniAb (OABI) Stock Up +0.70% Today?
Key Takeaways
- OABI shares closed at $4.33, up 0.70% ($0.03), extending a powerful multi-week advance.
- The gain capped a week in which the stock climbed roughly 28% and came within about 6% of its 52-week high of $4.59.
- Momentum traces back to a blowout Q2 report (revenue up 244% year over year) and a new Eli Lilly collaboration worth up to $370 million in milestones.
- Management raised guidance twice, lifting 2026 revenue to $32–36 million and year-end cash to $49–53 million.
- Volume ran well above average, while technical indicators signaled an extended, overbought setup.
- Traders are watching the October 6 Investor & Analyst Day and the Q3 earnings report expected in early November.
Opening Summary
OmniAb, Inc. (OABI), an Emeryville, California-based biotechnology company that licenses antibody-discovery technology to pharmaceutical and biotech partners, closed the latest session at $4.33, up 0.70% from the prior close of $4.30. The move confirmed the stock's upward trajectory, which has now carried shares roughly 105% higher over the past month and more than 134% higher year to date. Markets attributed the continued strength to a combination of a strong second-quarter earnings beat, an upgraded financial outlook, and a high-profile partnership with Eli Lilly announced earlier in the month.
Earnings Beat and Raised Guidance Fuel Momentum
The foundation of the rally was laid on August 6, when OmniAb reported second-quarter results that far exceeded Wall Street expectations. Total revenue reached $13.4 million, up 244% from $3.9 million a year earlier, while the net loss narrowed to $5.9 million, or $0.05 per share, from $15.9 million a year ago. The company beat consensus estimates of a $0.12-per-share loss and roughly $4.7 million in revenue, driven largely by milestone payments as partner programs advanced in clinical development.
Management followed the report by raising full-year 2026 revenue guidance to a range of $32 million to $36 million, and later lifted its year-end cash outlook to $49 million to $53 million from a prior $37 million to $41 million. The company ended the second quarter with 110 active partners, 425 active programs, 34 active clinical programs, and more than $3 billion in contracted potential milestone payments, reinforcing the long-term licensing story.
Eli Lilly Collaboration Anchors the Rally
The sharpest single catalyst arrived on August 17, when OmniAb announced a global collaboration and license agreement with Eli Lilly (LLY) for a new ion channel discovery program. Under the terms, Lilly will use OmniAb's ion channel discovery and screening capabilities, with OmniAb eligible for up to $370 million in research, development, and commercial milestone payments, plus tiered royalties on global net sales. The undisclosed upfront payment and expanded cash outlook reduced near-term dilution risk and gave management additional runway, factors that fueled a double-digit premarket surge that has since consolidated into a steady grind higher.
Analyst Support and Technical Momentum
Adding to the bullish backdrop, HC Wainwright reiterated a Buy rating with an $11 price target following the earnings and partnership news. On a technical basis, OABI trades well above its 50-day and 200-day moving averages, and its relative strength reading has been among the highest in the market. The stock broke decisively above its prior 52-week high near $3.63, which now serves as a key support level, though momentum indicators such as the RSI sit near overbought territory, signaling the possibility of profit-taking or consolidation.
Market Context and Trading Activity
The latest session was choppy rather than one-directional. Shares opened near $4.31, climbed to an intraday high of $4.535, pulled back to $4.14, and recovered to close at $4.33. Volume of roughly 1.85 million shares ran well above the stock's average of about one million, indicating sustained participation rather than a one-off spike. The advance has been largely company-specific: broader equity indices moved modestly, and the move reflects OmniAb-specific catalysts rather than broad sector sympathy, even as the biotech and life-sciences-tools complex has generally supported growth-stage names.
What Comes Next for OABI
Investors will look next to OmniAb's Investor & Analyst Day on October 6 and its third-quarter earnings report, expected in early November. Key drivers include continued advancement of partner programs, additional clinical entrants, and any further progress on the xPloration screening platform. Risks remain material: milestone revenue is inherently lumpy, the company is still unprofitable, and shares are technically extended after a triple-digit run. The stock's heavy reliance on partner decisions and clinical timelines means quarterly results can vary significantly, even as the contracted milestone base provides longer-term visibility.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of automated bots covering thousands of tickers, with strategies that differ by approach, timeframe, performance metrics, and traded symbols. Only those demonstrating standout results are featured in this section. Explore the Trending AI Robots to see which strategies are leading right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
OABI in -6.84% downward trend, declining for three consecutive days on September 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where OABI declined for three days, in 205 of 245 cases, the price declined further within the following month. The odds of a continued downward trend are 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for OABI moved out of overbought territory on September 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator moved out of overbought territory. In 26 of the 47 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OABI as a result. In 64 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for OABI turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 34 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 63 cases where OABI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
Following a +2.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where OABI advanced for three days, in 143 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 79 of 177 cases where OABI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 45%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.497) is normal, around the industry mean (25.929). P/E Ratio (0.000) is within average values for comparable stocks, (40.079). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.178). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (14.124) is also within normal values, averaging (437.043).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. OABI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OABI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement